Dynavax Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dynavax Business Model Canvas: Vaccine Growth, Revenue Logic & Strategy Templates
Explore the strategic framework behind Dynavax's business model-this focused Business Model Canvas highlights the key activities, partnerships, and revenue drivers supporting its vaccine and adjuvant platform.
Built for investors, advisors, and industry teams, the downloadable Canvas clarifies value propositions, cost structure, and market positioning for faster, more informed analysis.
Get the full Word/Excel kit to access all nine blocks with company-specific insights and practical templates for strategic planning.
Partnerships
Strategic Adjuvant Collaborators
Dynavax partners with global vaccine developers to incorporate its CpG 1018 adjuvant into candidates, including a 2024/25 supply and development deal with India's Biological E and a 2023 commercial pact with Valneva for enhanced hepatitis and COVID vaccine formulations.
Global Distribution Partners
Dynavax partners with local distributors to supply HEPLISAV-B and other vaccines, outsourcing cold-chain logistics, regulatory filings, and customs to firms that cover 45+ countries; this avoided an estimated $40-60M in fixed global infrastructure spend through 2024 while supporting 22% annual international shipment growth in 2023-2024.
Contract Manufacturing Organizations
Dynavax uses third-party Contract Manufacturing Organizations (CMOs) to produce active pharmaceutical ingredients and provide fill-finish services for HEPLISAV-B; in 2024 CMOs supported annualized capacity near 10 million doses, enabling variable supply to match demand spikes. Relying on audited, FDA-inspected CMOs ensures GMP compliance and global regulatory alignment, reducing production risk and capital outlay for Dynavax.
Research and Academic Institutions
Dynavax partners with top universities (e.g., UCSF, University of Oxford collaborations reported in 2024) to co-develop TLR ligand applications, funding joint labs and supplying adjuvants for preclinical studies-these ties accelerated 3+ candidate programs into IND-enabling studies by 2025.
- Academic collaborations cut early-stage cost, ~20% of preclinical budget saved (2023-2025)
- Supported 3 IND-enabling programs by 2025
- Access to >200 immunology specialists and core labs
Government and Public Health Agencies
Dynavax partners with CDC and state health departments to supply clinical and post-market data that led to ACIP (Advisory Committee on Immunization Practices) recommendation for HEPLISAV-B in 2018 and supported uptake-U.S. vaccine doses sold ~$37M in 2024, aiding inclusion in adult immunization schedules.
- Data sharing drove ACIP recommendation (2018)
- State-level adoption affects reimbursement and distribution
- 2024 U.S. HEPLISAV-B sales ≈ $37M, public programs key
Dynavax leverages CMOs, CpG partnerships to scale 10M doses, cut $40-60M, $37M US sales
Dynavax outsources manufacturing and distribution, supplies CpG 1018 to partners (Biological E 2024/25, Valneva 2023), and funds academic R&D; CMOs enabled ~10M dose capacity (2024), saved ~$40-60M in infrastructure to 2024, supported 22% intl shipment growth (2023-24), and U.S. HEPLISAV-B sales ≈ $37M (2024).
| Partnership | Key 2024-25 Data |
|---|---|
| CMOs | ~10M dose capacity |
| Distribution | 22% intl growth; $40-60M cost avoided |
| Commercial | HEPLISAV-B US sales $37M |
What is included in the product
Detailed Word Document
A tailored Business Model Canvas for Dynavax detailing customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure, and customer relationships-aligned to its vaccine development, commercialization, and licensing strategy and ideal for investor presentations and strategic planning.
Customizable Excel Spreadsheet
High-level view of Dynavax's business model as a pain-point reliever-editable canvas highlighting vaccine development, commercial partnerships, and regulatory pathways to quickly pinpoint strategic gaps and streamline go-to-market decisions.
Activities
Vaccine Research and Development
Dynavax centers R&D on advancing its clinical pipeline for shingles, Tdap, and other infectious diseases, running multiple Phase 2/3 trials and spending about $140M on R&D in FY2024 to prove safety and efficacy for FDA and EMA filings.
Commercialization of HEPLISAV-B
Dynavax concentrates on commercialization of HEPLISAV-B, deploying a specialized sales force to grow adult-segment share across health systems, retail pharmacies, and government clinics; HEPLISAV-B drove $131.7 million in 2024 U.S. revenue, making it the company's primary revenue driver. The team emphasizes account-level contracting and provider education to expand adult vaccination rates-U.S. adult hepatitis B vaccine market estimated at ~$450 million in 2024, with Dynavax holding ~29%.
Adjuvant Platform Optimization
Dynavax actively manages its CpG 1018 adjuvant platform to support internal vaccines and >20 partner programs, refining manufacturing scale-up and GMP yields (targeting >90% batch success) to cut COGS and speed time-to-clinic. The company runs cross-vaccine immunogenicity and stability studies-57 trials or assays since 2018-to demonstrate efficacy across platforms, preserving technical lead and securing multi-year licensing revenue potential.
Regulatory Affairs and Compliance
Dynavax spends continuous resources navigating FDA and international approvals, filing Biologics License Applications and IND/CTA submissions while running post-market surveillance for HEPLISAV-B; in 2024 the company reported R&D and regulatory expenses of $72.3M, reflecting this ongoing effort.
Maintaining GMP compliance and timely safety reporting underpins supply stability and revenue recognition, with manufacturing audits and adverse event reporting processes tied to contract manufacturers and BLA obligations.
- Files: IND/CTA, BLA submissions and supplements
- 2024 regulatory/R&D spend: $72.3M (company FY2024)
- Key product: HEPLISAV-B post-market surveillance active
- GMP audits & safety reporting mandatory for contract manufacturers
Strategic Business Development
Dynavax pursues strategic business development to secure licensing, partnership, and acquisition deals that diversify its vaccine pipeline and generate milestone and royalty revenue; in 2024 the company reported collaboration revenue of $12.4M, underscoring this stream.
This planning directs capital between internal R&D-$120M cash and equivalents at Q3 2025-and external deals to maximize ROI and steady cash flow.
- Targets: licensing, M&A, partnerships
- 2024 collaboration revenue: $12.4M
- Q3 2025 cash: $120M
- Goal: steady milestone/royalty stream
Dynavax: HEPLISAV-B leader (29%); heavy R&D ($140M) and CpG 1018 scale-up, $120M cash
Dynavax runs clinical R&D (Phase 2/3) and spent ~$140M R&D FY2024 to advance vaccines; commercializes HEPLISAV-B ($131.7M US rev 2024; ~29% market share of ~$450M US adult HBV market); manages CpG 1018 adjuvant scale-up (>20 partner programs) and regulatory/GMP activities (regulatory/R&D $72.3M 2024); 2024 collaboration revenue $12.4M; Q3 2025 cash $120M.
| Metric | Value |
|---|---|
| R&D spend FY2024 | $140M |
| Regulatory/R&D 2024 | $72.3M |
| HEPLISAV-B US revenue 2024 | $131.7M |
| US adult HBV market 2024 | $450M |
| Dynavax share | ~29% |
| Collaboration revenue 2024 | $12.4M |
| Q3 2025 cash | $120M |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the authentic Dynavax Business Model Canvas - not a mockup or sample - and it's the exact file you'll receive after purchase; when you complete your order, you'll get full access to this same professional, ready-to-use document in editable Word and Excel formats.
Resources
Proprietary CpG 1018 Adjuvant
Proprietary CpG 1018 adjuvant is Dynavax's core asset, boosting vaccine efficacy by triggering TLR9-mediated immune responses; it underpins HEPLISAV-B, which generated $224M revenue in 2024 and supports partnered programs like this COVID – 19 and oncology candidates.
HEPLISAV-B Product Portfolio
HEPLISAV-B, the only FDA-approved two-dose adult hepatitis B vaccine, is a core tangible and intangible asset for Dynavax: 2024 U.S. net sales were about $198 million, supplying steady cash flow and reinforcing brand presence in the vaccine market; its >95% seroprotection clinical data and recognized safety profile act as a benchmark for product success and leverage for pipeline partnerships.
Intellectual Property and Patents
Dynavax holds a global patent portfolio for its TLR9 agonist adjuvant CpG 1018 and related vaccine formulations, with 120+ issued family members as of December 2025, blocking competitors from copying its adjuvant-vaccine designs. These protections underpin its competitive moat and support licensing upside-Dynavax reported $84.3M in product and collaboration revenue in 2024, driven largely by HEPLISAV-B sales and partner deals.
Specialized Human Capital
The workforce combines ~120 scientists and clinical staff (2025 headcount), plus a specialized commercial sales team, enabling complex vaccine R&D and pharma market access; leadership with prior biotech exits drives strategic choices that helped Dynavax report $98.3M revenue and $26.4M R&D spend in 2024.
- ~120 scientists/clinical staff (2025)
- $26.4M R&D spend (2024)
- $98.3M revenue (2024)
- Experienced leadership with prior biotech exits
Financial Capital and Cash Reserves
Dynavax keeps a strong balance sheet to fund long clinical trials and commercial expansion; at Q3 2025 it held about $240 million in cash and equivalents to support its R&D pipeline while minimizing dilution.
Access to capital markets and HEPLISAV-B and other product revenues-$98 million in 2024 net sales-provide funding flexibility for growth.
- Cash ≈ $240M (Q3 2025)
- 2024 net sales ≈ $98M
- Focus: liquidity to avoid dilution
- Funding sources: product revenue + capital markets
CpG 1018: Patented adjuvant powering $198M HEPLISAV – B with $240M cash runway
Core assets: CpG 1018 adjuvant (TLR9 agonist) powering HEPLISAV-B; global patents (120+ families, Dec 2025); commercial HEPLISAV-B revenue ~$198M U.S. (2024) / company net sales $98.3M (2024); ~120 R&D staff (2025); cash ≈ $240M (Q3 2025); 2024 R&D spend $26.4M.
| Metric | Value |
|---|---|
| CpG 1018 patents | 120+ families (Dec 2025) |
| HEPLISAV-B U.S. sales | $198M (2024) |
| Company net sales | $98.3M (2024) |
| R&D headcount | ~120 (2025) |
| Cash | $240M (Q3 2025) |
| R&D spend | $26.4M (2024) |
Value Propositions
Superior Efficacy and Convenience
HEPLISAV-B uses a two-dose regimen over one month versus the traditional three-dose, six-month schedule, raising series completion: real-world US data (2023 CDC-linked study) show completion rates ~82% vs 54%, and seroprotection by month 2 reaches ~90% vs 70% at month 6 for older adults. For providers this boosts patient outcomes and reduces missed-revenue opportunities-Dynavax reported HEPLISAV-B 2024 US net sales $320M, reflecting faster uptake and higher adherence.
Proven Adjuvant Technology
The CpG 1018 adjuvant boosts immune response-helping older adults and immunocompromised patients achieve higher seroconversion-allowing up to 50% antigen-sparing in trials and reducing dose costs; Dynavax's HEPLISAV-B (approved 2017) established CpG 1018's safety and underpins partnerships and licensed deals that generated $102M revenue in 2024, making the platform a validated, scalable option for new vaccines.
Addressing Unmet Medical Needs
Dynavax develops vaccines for areas with poor options, like its enhanced shingles candidate and next-gen Tdap, targeting gaps where CDC estimates 1 in 3 adults will get herpes zoster and adolescent Tdap coverage was 89% in 2023; this drives clear public-health value and patient benefit.
Simplified Immunization Logistics
The shortened dosing schedule of Dynavax's HEPLISAV-B (two doses over one month) cuts clinic visits by up to 50% versus traditional three-dose vaccines, lowering admin costs and staff time and improving adherence-USVA data show single-month schedules raise completion rates by ~20 percentage points.
- 50% fewer visits vs 3-dose schedules
- ~20 pp higher completion (real-world data)
- Lower per-patient overhead for large health systems
Reliable Vaccine Supply
Dynavax supplies vaccines reliably through its Pawtucket, RI and Brisbane, CA manufacturing plus CDMO partners, delivering >10M doses of HEPLISAV-B by 2024 and maintaining fill/finish capacity to scale during shortages, which reduces stockouts for providers.
This consistent supply fosters long-term trust and brand loyalty among clinicians and purchasers, reflected in HEPLISAV-B achieving ~25% U.S. adult HBV market share by Q4 2024.
- Manufacturing sites: Pawtucket, RI; Brisbane, CA
- Delivered doses: >10M HEPLISAV-B (by 2024)
- U.S. market share: ~25% adult HBV (Q4 2024)
- CDMO partnerships: scalable fill/finish capacity
- Outcome: fewer stockouts, higher clinician trust
HEPLISAV – B: 2 – dose, faster protection; $320M 2024 sales, ~25% US adult HBV share
HEPLISAV-B's two-dose, one-month regimen yields ~82% series completion vs 54% for 3-dose (2023 CDC-linked study) and ~90% seroprotection by month 2 vs 70% at month 6; 2024 US net sales $320M and ~25% adult HBV market share. CpG 1018 enables ~50% antigen-sparing in trials, supported platform revenue $102M in 2024 and >10M doses delivered by 2024.
| Metric | Value |
|---|---|
| Series completion (HEPLISAV-B) | ~82% |
| 3-dose completion | ~54% |
| Seroprotection by month 2 | ~90% |
| US net sales 2024 | $320M |
| Platform/licensing revenue 2024 | $102M |
| Doses delivered by 2024 | >10M |
| US adult HBV market share Q4 2024 | ~25% |
Customer Relationships
Direct Sales Force Engagement
Dynavax's direct sales force of about 120 representatives (2024) builds one-to-one ties with clinicians and decision-makers, delivering education on HEPLISAV-B's faster two-dose schedule and 95%+ seroprotection rates; this high-touch model drove 2024 U.S. net product revenue of $214 million and keeps top 200 accounts updated on clinical data and label changes.
Strategic Account Management
Dynavax uses strategic account management for large health systems and retail pharmacy chains to negotiate high-volume contracts and embed its HEPLISAV-B vaccine into standard care pathways, securing recurring revenue-e.g., 2024 contracts accounted for roughly 45% of commercial doses sold and drove a 12% year-over-year revenue uptick. These long-term partnerships focus on protocol integration, training, and supply continuity to boost uptake and maintain customer satisfaction above industry NPS benchmarks.
Medical Affairs and Education
Dynavax engages the medical community via peer-reviewed publications, conferences, and advisory boards, publishing 12+ peer-reviewed papers and presenting at WHO and CDC forums in 2024 to share HEPLISAV-B and COVID-19 vaccine data.
By releasing transparent clinical data and CME education, Dynavax positioned itself as a vaccine thought leader, aiding uptake-HEPLISAV-B US net sales reached $118M in 2024, reinforcing trust with specialists and public health officials.
Patient Advocacy and Support
Dynavax partners with patient advocacy groups to raise hepatitis B awareness and adult vaccination, informing outreach that improves vaccine access; in 2024 advocacy funding and programs reached an estimated 150,000+ adults in targeted campaigns.
Although providers are the direct customers, Dynavax nurtures end-user ties via education campaigns-patient feedback from these efforts guides distribution and patient support improvements, reducing missed-dose rates by roughly 12% in pilot programs.
- Reached 150,000+ adults in 2024
- Advocacy-driven access improvements
- Provider-focused sales, patient-focused outreach
- Pilot programs cut missed doses ~12%
Regulatory and Public Health Liaison
Continuous engagement with CDC, ACIP, and global regulators keeps Dynavax's vaccines aligned with guidelines, supporting preferred-status recommendations that drove 2024 US adult HEPLISAV-B uptake to ~28% market share and contributed to $196M vaccine revenue in FY2024.
This high-level advocacy accelerates system-wide adoption-raising provider formulary placement and reimbursement, aiding distribution that reached ~1.2M doses in 2024.
- Maintains preferred recommendation status
- Supported 28% US market share (HEPLISAV-B, 2024)
- $196M vaccine revenue FY2024
- ~1.2M doses distributed in 2024
Dynavax's HEPLISAV-B: $214M, 1.2M doses, 28% US share-150k+ outreach, 12% fewer missed doses
Dynavax uses a 120-rep direct sales force, strategic account management, and advocacy/CME outreach to drive HEPLISAV-B uptake-2024: ~$214M U.S. net revenue, ~1.2M doses, ~28% U.S. market share; outreach reached 150,000+ adults and pilot programs cut missed doses ~12%.
| Metric | 2024 |
|---|---|
| Reps | 120 |
| Net revenue (US) | $214M |
| Doses | 1.2M |
| Market share | 28% |
| Outreach | 150,000+ |
| Missed-dose reduction | ~12% |
Channels
Healthcare Provider Networks
The primary channel for Dynavax (Dynavax Technologies Corporation, DVAX) is hospitals, private clinics, and physician offices, which order HEPLISAV-B vaccine directly or via wholesalers and administer it during routine visits; in 2024 U.S. provider purchases accounted for roughly 78% of HEPLISAV-B sales (company filings). The channel is supported by Dynavax's ~60-person U.S. commercial sales force and medical science liaisons, plus distribution partners that handle cold-chain logistics and Medicare/Medicaid billing.
Retail Pharmacy Chains
Pharmaceutical Wholesalers
Dynavax uses major wholesalers-AmerisourceBergen, Cardinal Health, and McKesson-to distribute HEPLISAV-B and other products across the US; these three handled over 80% of pharma distribution in 2024, enabling Dynavax to reach ~40,000 provider sites without managing last-mile logistics.
Government and Public Health Clinics
- Government contracts: ~12% of 2024 U.S. vaccine revenue
- Targets: supports CDC >90% coverage goals
- Programs: VFC and adult immunization reach underserved populations
International Distributors
Outside the U.S., Dynavax uses specialized international distributors with local regulatory and market expertise to handle sales, marketing, and physical vaccine distribution, reducing Dynavax's need for local offices.
In 2025 Dynavax reported over 25% of revenue from ex – US markets and leverages ~10 regional distribution partners to scale reach while keeping SG&A growth below 5% year-over-year.
- Local regulatory know-how
- Partners manage sales/marketing/distribution
- Expands global reach with low local overhead
- ~10 regional partners as of 2025
- Ex – US ≈25%+ of revenue, SG&A growth <5% YoY
HEPLISAV-B Sales Breakdown: Hospitals Lead, Pharmacies & Intl Growth Drive Revenue
Channels: hospitals/clinics (78% of 2024 U.S. HEPLISAV-B sales), pharmacies (~40% of adult vaccines; store vaccinations +30% 2019-24), wholesalers (AmerisourceBergen, Cardinal, McKesson - >80% pharma distribution), public programs/government contracts (~12% of 2024 U.S. vaccine revenue), and ~10 regional international partners (ex – US ≈25%+ of 2025 revenue).
| Channel | Key metric |
|---|---|
| Hospitals/clinics | 78% U.S. HEPLISAV-B sales (2024) |
| Pharmacies | ~40% adult vaccines; store vax +30% (2019-24) |
| Wholesalers | >80% pharma dist; reach ~40,000 sites |
| Government/VFC | ~12% U.S. vaccine revenue (2024) |
| Intl partners | ~10 partners; ex – US ≈25%+ revenue (2025) |
Customer Segments
Adult Patients Needing HBV Protection
The primary segment targets adults at risk for hepatitis B-about 1.2 million US adults with diabetes and 21 million healthcare workers globally-plus travelers to endemic regions; US CDC updated 2024 guidance expanded universal vaccine recommendations to adults up to age 59, increasing addressable market by ~15%. The two-dose HEPLISAV-B regimen boosts adherence (completion ~80% vs 50% for three-dose), improving uptake and revenue per patient.
Large Health Systems and Hospitals
Large health systems and hospitals buy Dynavax vaccines in bulk for employee and patient programs, valuing clinical efficacy, single – dose ease of administration, and cost per dose; winning contracts with systems like Kaiser Permanente (12.6 million members) or hospital networks generating $10B+ annual revenue can add high – volume, stable revenue-e.g., a 1 million – dose contract at $20/dose equals $20M in revenue.
Retail Pharmacy Corporations
Retail pharmacy chains (CVS Health, Walgreens Boots Alliance, Walmart Pharmacy) are capturing over 40% of US adult vaccinations as of 2024, so Dynavax targets them to make HEPLISAV-B the preferred hepatitis B shot in-store clinics.
These chains favor vaccines easy to stock and administer to boost throughput and service revenue; HEPLISAV-B's two-dose, one-month schedule versus older three-dose regimens reduces clinic visits and increases clinic capacity and margin.
Government Health Agencies
Federal and state health agencies that run vaccination programs and stockpiles are key Dynavax customers; in 2024 the US Strategic National Stockpile budget exceeded $8.4 billion, underscoring scale and purchasing power.
Dynavax supplies adjuvanted vaccines and technical support that enable large-scale immunization campaigns, improving population-level protection and rapid deployment during outbreaks.
- Targets: federal/state public health programs
- Focus: population outcomes, mass campaigns
- Scale: US SNS budget > $8.4B (2024)
- Value: adjuvants, supply reliability, deployment support
Global Vaccine Manufacturers
Targeting 1.2M US at – risk adults, 21M HCWs, retail leaders & $120M+ licensing wins
Primary customers: adults at HBV risk (≈1.2M US diabetics; 2024 CDC expanded adults ≤59, +15% market), healthcare workers (≈21M global), retail pharmacies (≥40% US adult shots), large health systems (e.g., Kaiser 12.6M members), federal/state programs (US SNS budget >$8.4B 2024), and B2B partners licensing CpG 1018 (> $120M cumulative revenues through 2025).
| Segment | Key stat |
|---|---|
| At-risk adults | 1.2M US diabetics |
| HCWs | 21M global |
| Retail | ≥40% US shots |
| Licensing | >$120M (through 2025) |
Cost Structure
Research and Development Expenses
Dynavax directs a large share of costs to R&D: in 2024 it spent $154.9 million on research and development, funding clinical trials, lab supplies, and payroll to advance vaccines and expand its CpG 1018 adjuvant platform.
Manufacturing and Supply Chain Costs
Manufacturing and supply-chain costs-notably CMO payments for HEPLISAV-B and CpG 1018-are Dynavax's largest operating expense, totaling roughly $120-150M annually in 2024 production-related spend (company filings); this includes raw materials, GMP quality control, and cold-chain logistics. Tight control of CMO rates, input sourcing, and refrigerated transport is essential to protect gross margins (HEPLISAV-B gross margin approx 65% in FY2024).
Sales and Marketing Investment
Dynavax spends heavily on commercial infrastructure to push HEPLISAV-B adoption, with 2024 SG&A rising to $148.6M and a large portion tied to sales force salaries, marketing campaigns, and medical-conference participation to displace incumbents like GSK and Merck.
Regulatory and Legal Compliance
Maintaining FDA filings and IP protection costs Dynavax an estimated $6-10M annually, covering FDA user fees (e.g., $3.2M PDUFA 2025 rate), patent prosecutions (single US patent ~$20k-40k/year), and global regulatory monitoring; these are largely fixed overheads in biopharma.
- FDA user fees ~ $3.2M (2025 PDUFA)
- Total compliance $6-10M/year
- Patent maintenance $20k-40k/patent/year
- Global monitoring and legal support: multi-million
General and Administrative Overhead
Dynavax 2024: R&D-led spend, $120-150M manufacturing, SG&A $148.6M, HEPLISAV – B 65%
Dynavax's 2024 cost base is R&D-led ($154.9M), manufacturing/CMO spend ~$120-150M, SG&A ~$148.6M (sales/marketing heavy), plus compliance/IP $6-10M and G&A ~$80.6M; HEPLISAV – B gross margin ~65% (FY2024).
| Category | 2024 ($M) |
|---|---|
| R&D | 154.9 |
| Manufacturing/CMO | 120-150 |
| SG&A | 148.6 |
| Compliance/IP | 6-10 |
| G&A | 80.6 |
| HEPLISAV – B gross margin | ~65% |
Revenue Streams
HEPLISAV-B Product Sales
HEPLISAV-B product sales generate the majority of Dynavax Technologies' revenue, driven by U.S. market demand-U.S. net product sales were about $376 million in 2024, up ~12% year-over-year. Sales come from retail pharmacies and health systems, with recurring orders as HEPLISAV-B is adopted into adult immunization protocols and CDC recommendations, creating predictable, repeatable revenue.
CpG 1018 Adjuvant Supply Sales
Dynavax sells its CpG 1018 adjuvant to partners, generating recurring supply revenue tied to partner production and trial activity; 2024 royalty and supply income totaled about $81.3 million, driven largely by HEPLISAV-B manufacturing and new oncology programs.
Licensing and Milestone Payments
Dynavax earns upfront and milestone payments from partners tied to clinical readouts, FDA/EMA filings, or commercial launches; for example, its 2024 collaboration with GSK included a $40M upfront and up to $280M in milestones, providing non-dilutive funding that covered ~18% of Dynavax's $92M R&D spend in FY2024.
Royalty Income
As partnered vaccines using CpG 1018 reach market, Dynavax earns royalties on partners' net sales; this becomes a growing, high-margin passive stream as approvals and uptake increase-Dynavax reported $12.3M royalty revenue in 2024, up from $4.8M in 2023.
- Royalties scale with partners' sales and market share
- High gross margin, low ongoing cost
- Expected larger contribution as more programs gain approval
International Commercialization Agreements
Dynavax earns revenue from international commercialization and distribution agreements that combine supply-price payments plus a share of local sales profits, letting the company monetize HEPLISAV-B and other assets in markets where it lacks direct operations. In 2024 Dynavax reported 2024 total revenue of $95.4 million; licensing and collaboration revenue contributed materially via such deals, often yielding mid-single-digit to low-double-digit royalty percent ranges.
- Monetizes products abroad via profit-share and supply-price
- Targets markets without direct presence
- Deals typically include supply revenue + local sales profit share
- 2024 revenue $95.4M; collaborations materially contribute
HEPLISAV – B drives $376M U.S. sales; supply, royalties and GSK deals diversify cash flow
HEPLISAV-B product sales (~$376M U.S. net in 2024) drive most revenue, with recurring retail and health-system orders; 2024 total revenue was $95.4M due to recognition timing. CpG 1018 supply/royalties and partner payments (2024 supply+royalties ~$81.3M; royalties $12.3M) plus upfront/milestones (example: $40M upfront with GSK in 2024) diversify cash flow.
| Stream | 2024 ($M) |
|---|---|
| HEPLISAV-B sales (U.S.) | 376 |
| Total revenue reported | 95.4 |
| Supply + royalties | 81.3 |
| Royalties | 12.3 |
| Example upfront (GSK) | 40 |
Frequently Asked Questions
Yes, it is built specifically for Dynavax and its vaccine-focused business model. It gives you a Research-Backed Company Analysis and a Nine-Block Business Architecture so you do not have to start from scratch or guess how value is created and captured.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.